Quick Answer
ATOSSA THERAPEUTICS, INC. reported Research And Development Expense of $21.19 million for the year ending 2025.
- ATOSSA THERAPEUTICS, INC. showed an increase of +50.1% in Research And Development Expense from 2024 to 2025.
- This data is from ATOSSA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2012: $418.0 thousand | Q2 2012: $543.1 thousand | Q3 2012: $548.1 thousand | Q1 2013: $220.2 thousand | Q2 2013: $190.0 thousand | Q3 2013: $321.1 thousand | Q1 2014: $422.5 thousand | Q2 2014: $510.8 thousand | Q3 2014: $923.2 thousand | Q1 2015: $565.8 thousand | Q2 2015: $373.5 thousand | Q3 2015: $949.0 thousand | Q1 2016: $150.0 thousand | Q2 2016: $169.0 thousand | Q3 2016: $85.0 thousand | Q1 2017: $544.3 thousand | Q2 2017: $824.1 thousand | Q3 2017: $742.5 thousand | Q1 2018: $471.0 thousand | Q2 2018: $1.47 million | Q3 2018: $1.42 million | Q1 2019: $1.45 million | Q2 2019: $2.61 million | Q3 2019: $1.68 million | Q1 2020: $938.6 thousand | Q2 2020: $1.65 million | Q3 2020: $1.66 million | Q1 2021: $1.38 million | Q2 2021: $3.80 million | Q3 2021: $2.21 million | Q1 2022: $1.50 million | Q2 2022: $3.43 million | Q3 2022: $5.16 million | Q1 2023: $3.51 million | Q2 2023: $3.71 million | Q3 2023: $4.47 million | Q1 2024: $3.75 million | Q2 2024: $3.55 million | Q3 2024: $3.41 million | Q1 2025: $4.16 million | Q2 2025: $5.50 million | Q3 2025: $5.37 million.
- Over the full 14 years of available data (2012 to 2025), ATOSSA THERAPEUTICS, INC.'s Research And Development Expense has grown by 973.2%.
- Historical annual values: Fiscal year 2025: $21.19 million | Fiscal year 2024: $14.12 million | Fiscal year 2023: $17.33 million | Fiscal year 2022: $15.08 million | Fiscal year 2021: $9.21 million | Fiscal year 2020: $6.61 million | Fiscal year 2019: $6.65 million | Fiscal year 2018: $4.21 million | Fiscal year 2017: $2.33 million | Fiscal year 2016: $770.4 thousand | Fiscal year 2015: $2.36 million | Fiscal year 2014: $1.11 million | Fiscal year 2013: $1.11 million | Fiscal year 2012: $1.97 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: